MOA Life Plus Co. Ltd. (142760.KQ)
KOSDAQ · KRW · Healthcare · Biotechnology
₩366 (-12.86%) as of
Key statistics
- Market cap
- 7.72B
- Dividend yield
- 0.00%
- 52-week range
- 348.00 – 3,788.00
- Beta
- 0.58
- Revenue (TTM)
- 10.46B
- Profit margin
- -131.90%
- Volume
- 703.35k
About MOA Life Plus Co. Ltd.
MOA Life Plus Co. Ltd. engages in the medicine and consumer business in South Korea. It offers P53, a target anti-cancer drug. The company's pipeline products include BLS-H01, which is in phase 3 clinical trial for the treatment of cervical cancer; BLC-H03, a vaccine adjuvant that is in preclinical stage; BLS-M07 that has completed phase 2b clinical trial for the treatment of cervical cancer; and BLS-M22 that has completed phase 1 clinical trial for the treatment of Duchenne muscular dystrophy. It also provides health functional food and raw materials, and cosmetics. The company was formerly known as Bioleaders Corporation and changed its name to MOA Life Plus Co. Ltd. in March 2024. MOA Life Plus Co. Ltd. was founded in 1999 and is headquartered in Yongin-Si, South Korea.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Yongin-Si, South Korea
- Employees
- 47
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.